Results 241 to 250 of about 18,395 (294)

Functional characterization of podocyte-expressed THSD7A in experimental membranous nephropathy. [PDF]

open access: yesJCI Insight
Huang M   +15 more
europepmc   +1 more source

A Case Report of a Special Type of Multiple Myeloma: Kappa Light Chain‐Only

open access: yesOrgan Medicine, Volume 3, Issue 2, Page 119-124, June 2026.
This case illustrates the clinical course of a patient diagnosed with kappa light chain‐only multiple myeloma, a rare subtype of multiple myeloma. Of note, light chain multiple myeloma is characterized by rapid disease progression and severe target organ damage.
Yanhua Dai   +8 more
wiley   +1 more source

Povetacicept for IgA Nephropathy and Primary Membranous Nephropathy. [PDF]

open access: yesKidney Int Rep
Madan A   +16 more
europepmc   +1 more source

Kidney Stone, Nutritional Perceptions and Impact of Tea on Stone Formation

open access: yesPhytochemicals in Food and Medicine, Volume 1, Issue 2, June 2026.
ABSTRACT The significant financial burden that urinary stone disease places on healthcare systems is only anticipated to increase over time. It is becoming more common over the globe. It is an increasing urinary condition that impacts around 12% of the global population, and environmental variables appear to be a key contributor.
Munir Ahmed   +5 more
wiley   +1 more source

Migrasomes, Matrix‐Bound Nanovesicles, and More: Messengers in the Matrix

open access: yesPROTEOMICS, Volume 26, Issue 6, Page 9-21, June 2026.
ABSTRACT Extracellular vesicles (EVs) and particles (EPs) are diverse micro‐ and nanoparticles that circulate in bodily fluids and can attach to, or be deposited onto, the extracellular matrix (ECM) and other surfaces. To date, the nomenclature and classification of matrix‐bound or matrix‐associated EVs and EPs (MEVPs) have been unclear, largely due to
Anna V. Kolesov   +3 more
wiley   +1 more source

Joint modeling of longitudinal and time‐to‐event data for dynamic disease risk prediction using proteomics

open access: yesProtein Science, Volume 35, Issue 6, June 2026.
Abstract Biomedical studies increasingly incorporate longitudinal data, enabling us to track individual disease processes over time at the molecular level, and to discover associations of the molecular profiles with the outcome of interest, such as the onset of a disease.
Markus Lindén   +4 more
wiley   +1 more source

Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Rituximab is an anti‐CD20 monoclonal antibody used in autoimmune diseases, including glomerular diseases. The FCGR2A (rs1801274) and FCGR3A (rs396991) variants have been suggested to affect rituximab efficacy; this study evaluates their impact on rituximab efficacy in glomerular diseases.
María Larrosa‐García   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy